Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BRNS Barinthus Biotherapeutics	$1.19 +0.4%	$1.21	$0.64 ▼ $2.92	$47.60M	-0.73	53,681 shs	6,823 shs
DERM Journey Medical	$7.47 +5.5%	$7.16	$3.54 ▼ $8.90	$174.02M	0.8	188,629 shs	239,603 shs
SXTC China SXT Pharmaceuticals	$1.57	$1.68	$0.95 ▼ $7.84	$182.16M	1.24	40,649 shs	17,398 shs
TVGN Tevogen Bio	$0.94 +3.5%	$1.11	$0.26 ▼ $3.09	$172.20M	-0.77	1.46 million shs	456,978 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BRNS Barinthus Biotherapeutics	0.00%	-5.18%	-31.81%	+81.96%	-6.30%
DERM Journey Medical	0.00%	+7.48%	-2.61%	+6.71%	+69.77%
SXTC China SXT Pharmaceuticals	0.00%	-2.48%	-3.09%	+1.29%	-77.18%
TVGN Tevogen Bio	0.00%	-1.25%	-12.49%	-28.52%	+51.52%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BRNS Barinthus Biotherapeutics	3.2092 of 5 stars	3.5	3.0	3.6	0.8	1.3
DERM Journey Medical	1.6232 of 5 stars	3.2	1.0	2.3	0.8	0.6
SXTC China SXT Pharmaceuticals	0.74 of 5 stars	0.0	3.0	3.3	0.0	0.6
TVGN Tevogen Bio	3.9887 of 5 stars	3.5	3.0	3.3	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BRNS Barinthus Biotherapeutics	3.00	Buy	$3.00	152.10% Upside
DERM Journey Medical	2.33	Hold	$11.75	57.30% Upside
SXTC China SXT Pharmaceuticals	0.00	N/A	N/A	N/A
TVGN Tevogen Bio	3.00	Buy	$10.00	967.92% Upside

Current Analyst Ratings Breakdown

Latest BRNS, SXTC, DERM, and TVGN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/18/2025	TVGN Tevogen Bio	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
8/15/2025	DERM Journey Medical	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
8/13/2025	DERM Journey Medical	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$9.00 ➝ $13.00
8/4/2025	TVGN Tevogen Bio	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
6/18/2025	TVGN Tevogen Bio	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
6/10/2025	TVGN Tevogen Bio	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
5/27/2025	TVGN Tevogen Bio	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00

(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BRNS Barinthus Biotherapeutics	$14.97M	3.21	N/A	N/A	$2.54 per share	0.47
DERM Journey Medical	$56.13M	3.10	N/A	N/A	$0.83 per share	9.00
SXTC China SXT Pharmaceuticals	$1.74M	104.69	N/A	N/A	$21.35 per share	0.07
TVGN Tevogen Bio	N/A	N/A	N/A	N/A	($0.10) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BRNS Barinthus Biotherapeutics	-$61.07M	-$1.73	N/A	N/A	N/A	N/A	-54.70%	-44.75%	11/5/2025 (Estimated)
DERM Journey Medical	-$14.67M	-$0.38	N/A	N/A	N/A	-15.49%	-48.69%	-11.26%	11/11/2025 (Estimated)
SXTC China SXT Pharmaceuticals	-$3.30M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
TVGN Tevogen Bio	-$13.73M	N/A	0.00	∞	N/A	N/A	N/A	-775.49%	11/10/2025 (Estimated)

Latest BRNS, SXTC, DERM, and TVGN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/19/2025	N/A	TVGN Tevogen Bio	-$0.05	-$0.03	+$0.02	-$0.03	N/A	N/A
8/12/2025	Q2 2025	DERM Journey Medical	-$0.07	-$0.16	-$0.09	-$0.16	$14.93 million	$15.01 million
8/7/2025	Q2 2025	BRNS Barinthus Biotherapeutics	-$0.29	-$0.52	-$0.23	-$0.52	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BRNS Barinthus Biotherapeutics	N/A	N/A	N/A	N/A	N/A
DERM Journey Medical	N/A	N/A	N/A	N/A	N/A
SXTC China SXT Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
TVGN Tevogen Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BRNS Barinthus Biotherapeutics	N/A	7.89	7.89
DERM Journey Medical	1.11	1.27	0.95
SXTC China SXT Pharmaceuticals	0.01	3.54	3.40
TVGN Tevogen Bio	N/A	0.26	0.35

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BRNS Barinthus Biotherapeutics	25.20%
DERM Journey Medical	7.25%
SXTC China SXT Pharmaceuticals	5.02%
TVGN Tevogen Bio	N/A

Insider Ownership

Company	Insider Ownership
BRNS Barinthus Biotherapeutics	10.70%
DERM Journey Medical	15.03%
SXTC China SXT Pharmaceuticals	3.95%
TVGN Tevogen Bio	73.24%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BRNS Barinthus Biotherapeutics	107	40.34 million	36.02 million	N/A
DERM Journey Medical	90	23.30 million	19.80 million	N/A
SXTC China SXT Pharmaceuticals	90	116.03 million	111.45 million	Not Optionable
TVGN Tevogen Bio	3	183.89 million	49.21 million	N/A

BRNS, SXTC, DERM, and TVGN Headlines

Recent News About These Companies

Tevogen Recognized in BINJE’s BEST Health Care 2025 for Advancing Health Equity and Sustainable Biopharma

August 22 at 12:13 AM | markets.businessinsider.com

Tevogen Bio Holdings Inc. Recognized in BINJE's BEST Health Care 2025 for Commitment to Health Equity and Innovation

August 22 at 3:51 PM | quiverquant.comQ

Tevogen Recognized in BINJE's BEST Health Care 2025 for Advancing Health Equity and Sustainable Biopharma

August 22 at 3:25 PM | globenewswire.com

Tevogen Bio (NASDAQ:TVGN) Announces Earnings Results

August 21 at 5:28 PM | marketbeat.com

D. Boral Capital Reiterates Buy Rating for Tevogen Bio (NASDAQ:TVGN)

August 20, 2025 | marketbeat.com

Tevogen finalizes agreement for up to $50M in financing

August 19, 2025 | msn.com

REPEAT -- Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance ...

August 19, 2025 | bakersfield.comB

REPEAT -- Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development Efforts

August 19, 2025 | globenewswire.com

Tevogen Bio Holdings Inc. Reports Q2 2025 Financial Results with Reduced Loss from Operations and Focus on Growth Strategy

August 19, 2025 | quiverquant.comQ

Tevogen Delivers Stronger Second Quarter and First Half 2025 Financial Results with Reduced Expenses and Growth Momentum

August 19, 2025 | globenewswire.com

Tevogen CEO Donates Personal Shares to Support Local Law Enforcement

August 18, 2025 | globenewswire.com

Tevogen CEO Donates Personal Shares to Support Brain Injury Recovery

August 18, 2025 | globenewswire.com

Semper Paratus Acquisition (NASDAQ:TVGN) Stock Price Down 3% - Here's What Happened

August 16, 2025 | marketbeat.com

Tevogen to Release Internal Asset Valuation; CEO Affirms Assets Are Fully Protected

August 14, 2025 | globenewswire.com

Repeat - Tevogen.AI Expands Collaboration With Databricks and Microsoft to Build the Beta Version of Its PredicTcell™ Model With a Focus on Oncology

August 13, 2025 | globenewswire.com

Tevogen Bio Reaffirms Investor Confidence with Estimated Asset Value Exceeding $10 Billion

August 11, 2025 | globenewswire.com

REPEAT -- Tevogen Bio Specialty Care Reports Top-Line Revenue Forecast of Nearly $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $18 Billion and $22 Billion

August 11, 2025 | globenewswire.com

Tevogen Bio Oncology Reports Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion; Forecasts for Non-Oncology Therapeutic Areas to Follow

August 11, 2025 | globenewswire.com

REPEAT - Tevogen CEO Affirms Strong Growth, Capital Position, and AI Expansion in Letter to Stockholders

August 11, 2025 | globenewswire.com

REPEAT - Tevogen Sees Significant Institutional Ownership Growth; 73% of Holders Increase Positions

August 8, 2025 | globenewswire.com

Tevogen Receives $1 Million to Accelerate AI-Driven Drug Discovery; Remains Well Capitalized to Execute Growth Strategy

August 7, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BRNS, SXTC, DERM, and TVGN Company Descriptions

Barinthus Biotherapeutics NASDAQ:BRNS

$1.19 +0.01 (+0.42%)

Closing price 08/22/2025 03:50 PM Eastern

Extended Trading

$1.21 +0.02 (+1.68%)

As of 08/22/2025 04:54 PM Eastern

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer. It is also involved in the development of partnered candidates, such as AB-729-202, which is under phase 2a studies for the treatment of patients with chronic HBV infection; VTP-600, an immunotherapy candidate under phase 1 studies as a potential treatment for NSCLC in combination with standard of care treatment, chemotherapy, and pembrolizumab; VTP-500, a prophylactic vaccine product candidate under phase 1 studies to prevent infection and subsequent disease caused by the MERS coronavirus; and VTP-400, a prophylactic vaccine candidate under phase 1 studies to prevent shingles in adults aged 50 years and older. In addition, the company offers Vaxzevria (formerly VTP-900 and AZD1222), a prophylactic vaccine for the prevention of COVID-19 Infection. Further, it has license, research and development, and collaboration agreements with OUI, NIH, IMC, CanSino, CRUK; VOLT; and Arbutus. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Didcot, the United Kingdom.

Journey Medical NASDAQ:DERM

$7.47 +0.39 (+5.51%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$7.49 +0.02 (+0.27%)

As of 08/22/2025 04:10 PM Eastern

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm cream and solution an antifungal intended for topical use; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; and Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. In addition, the company sells sulconazole nitrate cream and solution indicated for the treatment of tinea cruris, tinea corporis, and tinea versicolor; and doxycycline hyclate tablets, as an adjunctive therapy for severe acne. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona. Journey Medical Corporation is a subsidiary of Fortress Biotech, Inc.

China SXT Pharmaceuticals NASDAQ:SXTC

$1.57 0.00 (0.00%)

Closing price 08/22/2025 03:55 PM Eastern

Extended Trading

$1.57 +0.00 (+0.25%)

As of 08/22/2025 04:12 PM Eastern

China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers advanced, fine, and regular TCMP products, and raw medicinal material, such as ChenXiang, SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. The company had an end-customer base of pharmaceutical companies, chain pharmacies, and hospitals in 10 provinces and municipalities in China. China SXT Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Taizhou, China.

Tevogen Bio NASDAQ:TVGN

$0.94 +0.03 (+3.54%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$0.92 -0.02 (-1.86%)

As of 08/22/2025 07:47 PM Eastern

Tevogen Bio Holdings Inc. operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients. It is also developing TVGN 601 for treating multiple sclerosis; TVGN 930 for the treatment of Epstein-Barr virus associated lymphomas; TVGN 920 for treating cervical cancer; and TVGN 960 for the treatment of mouth and throat cancer. The company was founded in 2020 and is headquartered in Warren, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time